Vantictumab
Vantictumab /vænˈtɪktʊmæb/ is a human IgG2 monoclonal antibody designed for the treatment of cancer.[1]
Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | Frizzled receptor |
Clinical data | |
Routes of administration | IV |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6322H9722N1674O1988S46 |
Molar mass | 142461.81 g·mol−1 |
This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer.[2] OncoMed was awarded a patent in 2016, which is set to expire in 2029.[3] In April 2017, Bayer terminated its option to license vanticitumab.[4]
It inhibits wnt signalling by targeting the frizzled receptors on cancer cells.[5]
Phase I trials have been completed for pancreatic cancer, non-small cell lung cancer, and breast cancer. In 2016 results were reported from a phase 1b clinical trial for triple-negative breast cancer.[5]
References
- "Statement on a nonproprietary name adopted by the USAN Council" (PDF). AMA. 28 Nov 2012. N12/155.(registration required)
- https://globenewswire.com/news-release/2015/01/12/696685/10115034/en/OncoMed-Pre-Announces-2014-Year-End-Cash-Balance-and-Provides-2015-Guidance.html
- http://investor.shareholder.com/oncomed/secfiling.cfm?filingID=1564590-16-14426&CIK=1302573
- https://www.reuters.com/article/brief-oncomed-pharmaceuticals-announces-idUSASA09I3R
- Finally, targeted therapies for triple-negative breast cancer. June 2016
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.